Search Results for: Nucleotides

June 12, 2019June 12, 2019

Lowering Mutant Huntingtin Using Tricyclo-DNA Antisense Oligonucleotides As a Therapeutic Approach for Huntington’s Disease.

Publication date: Jun 11, 2019 Huntington’s disease is a neurodegenerative disorder caused by a CAG repeat expansion in the first exon of huntingtin gene (HTT) encoding for a toxic polyglutamine ... Read more

May 18, 2019May 18, 2019

Targeted Oligonucleotides for Treating Neurodegenerative Tandem Repeat Diseases.

Huntington's Disease Literature

Publication date: May 16, 2019 Nucleotide repeat disorders encompass more than 30 diseases, most of which show dominant inheritance, such as Huntington’s disease, spinocerebellar ataxias, and myotonic dystrophies. Yet others, ... Read more

April 20, 2019April 20, 2019

Advances in the Understanding of Skin Cancer: Ultraviolet Radiation, Mutations, and Antisense Oligonucleotides as Anticancer Drugs.

Melanoma Literature

Publication date: Apr 17, 2019 Skin cancer has always been and remains the leader among all tumors in terms of occurrence. One of the main factors responsible for skin cancer, ... Read more

April 7, 2018April 7, 2018

Dose-Dependent Lowering of Mutant Huntingtin Using Antisense Oligonucleotides in Huntington Disease Patients.

Huntington's Disease Literature

Publication date: Apr 01, 2018 On December 11 of 2017, Ionis Pharmaceuticals published a press release announcing dose-dependent reductions of mutant huntingtin protein in their HTTRx Phase 1/2a study in ... Read more

July 21, 2019July 21, 2019

SREBP1-dependent de novo fatty acid synthesis gene expression is elevated in malignant melanoma and represents a cellular survival trait.

Melanoma Literature

Publication date: Jul 17, 2019 de novo fatty acid biosynthesis (DNFA) is a hallmark adaptation of many cancers that supports survival, proliferation, and metastasis. Here we elucidate previously unexplored aspects ... Read more

July 11, 2019July 11, 2019

Antisense therapies for movement disorders.

Huntington's Disease Literature

Publication date: Jul 08, 2019 Currently, few disease-modifying therapies exist for degenerative movement disorders. Antisense oligonucleotides are small DNA oligonucleotides, usually encompassing ∼20 base pairs, that can potentially target any ... Read more

July 11, 2019July 11, 2019

Antisense Oligonucleotide Therapies for Neurodegenerative Diseases.

Multiple Sclerosis Literature

Publication date: Jul 08, 2019 Antisense oligonucleotides represent a novel therapeutic platform for the discovery of medicines that have the potential to treat most neurodegenerative diseases. Antisense drugs are currently ... Read more

July 9, 2019July 9, 2019

Why the absence of hope may be hurting Huntington’s disease research

Huntington's Disease News

Publication date: Jul 09, 2019 The author of those words is George Huntington, the physician credited with defining the disease that carries his name, Huntington’s Disease, a genetic, invariably fatal, ... Read more

July 4, 2019July 4, 2019

Expert Briefing Webinar: What’s New in Genetics and Parkinson’s

Parkinson's Disease Media

Publication date: Jul 03, 2019 Presenter: Mathew Farrer, PhD Concepts Keywords Abbott Laboratories Degradation machinery light Abstinence Large pharmaceutical Acronym Internet s Alehouse Carrier reach years Alternator Pharmaceutical industries Antibodies ... Read more

July 3, 2019July 3, 2019

FEFU scientists teamed up with colleagues to develop ointment for skin cancer prevention

Melanoma News

Publication date: Jul 01, 2019 Scientists from Far Eastern Federal University (FEFU), V. I. Vernadsky Crimean Federal University, Dmitry Mendeleev University of Chemical Technology, and Far Eastern Branch of the ... Read more